← Back to Search

Other

ABBV-444 Drops for Dry Eye Syndrome

Phase 3

Waitlist Available

Research Sponsored by AbbVie

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to day 30

Awards & highlights

Study Summary

This trial will test a new drug to treat Dry Eye Disease. 40 adult participants will receive ABBV-444 eye drops as needed for 30 days to evaluate symptoms & tolerability. They will have regular visits & assessments, & may experience higher treatment burden than usual.

Eligible Conditions

Dry Eye Syndrome

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to day 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to day 30

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from Baseline in Ocular Surface Disease Index (OSDI) Score

Secondary outcome measures

Change from Baseline in Patient Eye Drop Experiences (Visual Analog Scale)

Change from Baseline in Symptom Scores (Visual Analog Scale) within 5 Minutes Post Administration of ABBV-444

Trial Design

1Treatment groups

Experimental Treatment

Group I: ABBV-444Experimental Treatment1 Intervention

Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ABBV-444

2023

Completed Phase 3

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor

954 Previous Clinical Trials

501,065 Total Patients Enrolled

ABBVIE INC.Study DirectorAbbVie

394 Previous Clinical Trials

145,899 Total Patients Enrolled

Media Library

ABBV-444 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05878067 — Phase 3

Dry Eye Syndrome Research Study Groups: ABBV-444

Dry Eye Syndrome Clinical Trial 2023: ABBV-444 Highlights & Side Effects. Trial Name: NCT05878067 — Phase 3

ABBV-444 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05878067 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has ABBV-444 obtained regulatory approval from the US Food and Drug Administration?

"According to our assessment, ABBV-444 is relatively safe with a rating of 3 due to the evidence collected from efficacy tests and multiple safety trials."

Answered by AI

Are any participants still being enrolled in this research endeavor?

"This experiment, which has been listed on clinicaltrials.gov since May 31st 2023 and revised as recently as the 24th of that same month, is actively looking for participants to join its ranks."

Answered by AI

What is the scale of participation for this experiment?

"Affirmative. Documentation on clinicaltrials.gov attests to this trial's active recruitment status, which began May 31st 2023 and was last edited on the 24th of that same month. 40 individuals are needed at one medical centre for participation in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

2023. "A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05878067.